Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France;Utilisation du rt-PA intraveineux dans l'ischémie cérébrale en centre hospitalier général: L'expérience de l'Hôpital Saint-Jean de Perpignan

Revue Neurologique

Volumn 162, Issue 11, 2006, Pages 1109-1117

  Sablot, D ^a   Cassarini, J F ^a   Akouz, A ^a   Benejean, J M ^a   Leibinger, F ^a   Faillie, X ^a   Vidry, E ^a   Ayrignac, X ^a   Castro, S ^a   Sinaya, L ^a   Bertrand, J L ^a   Garcia, Y ^a   Arnoud, B ^a   Negre, C ^a  

^a Hôpital Saint Jean   (France)

Author keywords

Brain ischemia; Stroke; Stroke Unit; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; COMMUNITY HOSPITAL; CONTROLLED STUDY; DEATH; DRUG SAFETY; FEMALE; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; RANKIN SCALE; TREATMENT OUTCOME;

EID: 33750715702     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-3787(06)75123-2     Document Type: Article

References (34)

1. ADAMS HP, BENDIXEN BH, KAPPELLE LJ, BILLER J, LOVE BB, GORDON DL, MARSH EE. (1993). Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 24: 35-41.
2. ADAMS HP, BROTT TG, FURLAN AJ et al. (1996). Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke, 27: 1711-1718.
3. ALBERS GW, BATES VE, CLARK WM, BELL R, VERRO P, HAMILTON SA. (2000). Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA, 283: 1145-1150.
4. BARBER PA, DEMCHUK AM, ZHANG J, BUCHAN AM. (2000). Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet, 355(9216): 1670-1674.
5. BARBER PA, ZHANG J, DEMCHUK AM, HILL MD, BUCHAN AM. (2001). Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology, 56: 1015-1020.
6. CHAPMAN K, WOOLFENDEN A, GRAEB D, JOHNSTON D, BECKMAN J, SCHULZER M, TEAL PA. (2000). Intravenous tissue plasminogen activator for acute ischemic stroke: a Canadian hospital's experience. Stroke, 31: 2920-2924.
7. CHIU D, KRIEGER D, VILLAR-CORDOVA C et al. (1998). Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke, 29: 18-22.
8. CLARK WM, WISSMAN S, ALBERS GW, JHAMANDAS JH, MADDEN KP, HAMILTON S. (1999). Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study: a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA, 282: 2019-2026.
9. FURLAN A, HIGASHIDA R, WECHSLER L et al. (1999). Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral Thromboembolism. JAMA, 282: 2003-2011.
10. GORDON DL, BENDIXEN BH, ADAMS HP, CLARKE W, KAPPELLE LJ, WOOLSON RF, and the TOAST Investigators. (1993). Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. Neurology, 43: 1021-1027.
11. HACKE W, KASTE M, FIESCHI C et al., FOR THE ECASS STUDY GROUP. (1995). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA, 274: 1017-1059.
12. HACKE W, KASTE M, FIESCHI C et al. (1998a). Randomized double blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet, 352: 1245-1251.
13. HACKE W, BLUHMKI E, STEINER T, TATLISUMAK T, MAHAGNE MH, SACCHETTI ML, MEIER D. (1998b). Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke, 29: 2073-2075.
14. HACKE W, DONNAN G, FIESCHI C et al. (2004). ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, 363(9411): 768-774.
15. HACKE W, ALBERS G, AL-RAWI Y et al., FOR THE DIAS STUDY GROUP (2005). The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke, 36: 66-73.
16. HJORT N, BUTCHER K, DAVIS SM et al., ON BEHALF OF THE UCLA THROMBOLYSIS INVESTIGATORS. (2005). Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke, 36: 388-397.
17. KLEINDORFER D, KISSELA B, SCHNEIDER A et al., FOR THE NEUROSCIENCE INSTITUTE. (2004). Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke, 35: 27-29.
18. LARRUE V, AMARENCO P, CAUSSANEL JP, DUCROCQ X, LUCAS C, MAHAGNE MH, ROUANET F POUR LA SOCIÉTÉ FRANÇAISE NEUROVASCULAIRE. (2000). Recommandations pour l'utilisation du traitement thrombolytique intra-veineux dans l'accident ischémique cérébral. Rev Neurol (Paris), 156: 1178-1185.
19. MOULIN T, CREPIN-LEBLOND T, CHOPARD JL, BOGOUSSLAVSKY J. (1994). Hemorrhagic infarcts. Eur Neurol, 34: 64-77.
20. MOULIN T, SABLOT D, VIDRY E et al. (2003). Impact of emergency room neurologists on patient management and outcome. Eur Neurol, 50: 207-214.
21. THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE RT-PA STROKE STUDY GROUP. (1995). Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 333: 1581-1587.
22. OPPENHEIM C, SAMSON Y, DORMONT D et al. (2002). DWI prediction of symptomatic hemorrhagic transformation in acute MCA infarct. J Neuroradiol, 29: 6-13.
23. RIBO M, MOLINA CA, ROVIRA A et al. (2005). Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke, 36: 602-606.
24. ROTHWELL PM, COULL AJ, SILVER LE et al. for the Oxford Vascular Study. (2005). Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet, 366: 1773-1783.
25. SABLOT D, BELAHSEN F, VUILLIER F, TATU L, MOULIN T. (2003a). Hémiplégies d'installation soudaine. Encycl Méd Chir (Éditions scientifiques et médicales Elsevier SAS, Paris), Urgences, 24-002-C-10, 15p.
26. SABLOT D, BELAHSEN F, VUILLIER F, TATU L, MOULIN T. (2003b). Syndromes anatomocliniques des infarctus du territoire de l'artère carotide. Encycl Méd Chir (Éditions scientifiques et médicales Elsevier SAS, Paris), Neurologie, 17-046-A-30, 12p.
27. TANNE D, BATES V, VERRO P et al., AND THE T-PA STROKE SURVEY GROUP. (1999). Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology, 53: 424-427.
28. TATU L, MOULIN T, BOGOUSSLAVSKY J, DUVERNOY H. (1996). Arterial territories of human brain: brainstem and cerebellum. Neurology, 47: 1125-1135.
29. TATU L, MOULIN T, BOGOUSSLAVSKY J, DUVERNOY H. (1998). Arterial territories of the human brain: cerebral hemispheres. Neurology, 50: 1699-1708.
30. TROUILLAS P, NIGHOGHOSSIAN N, DEREX L et al. (1998). Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke, 29: 2529-2540.
31. VON KUMMER R, ALLEN KL, HOLLE R et al. (1997). Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology, 205: 327-333.
32. WARDLAW JM, YAMAGUCHI T, DEL ZOPPO G. (1999). Thrombolytic therapy versus control in acute ischaemic stroke (Cochrane Review): In: The Cochrane Library: Issue 3. Oxford, UK: Update Software.
33. WINTERMARK M, REICHHART M, CUISENAIRE O et al. (2002). Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke, 33: 2025-2031.
34. WOIMANT F POUR LA SOCIÉTÉ FRANÇAISE NEURO-VASCULAIRE. (2001). Recommandations pour la création d'Unités Neuro-Vasculaires. Rev Neurol (Paris), 157: 1447-1456.